 Home > Active Ingredient News > Drugs Articles > Inventory of the top 10 financing of medical technology companies in 2021, what are their characteristics?

Inventory of the top 10 financing of medical technology companies in 2021, what are their characteristics?

 Last Update: 2022-04-28
 Source: Internet
 Author: User

Tags

cell pellet

enabling technologies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On March 21, Fierce Medtech announced on its official website a list of 10 medical technology companies that will receive high financing in 2021
.

The article points out that the total amount of financing for medtech companies in 2021 exceeds $11.

The total amount raised by medtech companies in 2021 exceeds $11.

Financing Finance: $830 million

Funding round: Undisclosed

In May 2021, Caris Life Sciences announced a $830 million round led by Sixth Street
.

Focused on driving innovation in molecular science and artificial intelligence in precision medicine, Caris hopes to develop liquid biopsy technology to detect early-stage cancers from a single blood sample

Hope to develop liquid biopsy technology to detect early stage cancer from a single blood sample multi-omics sequencing platform technology

2.
CMR Surgical

Financing Finance: $600 million

Financing round: D round

In June 2021, CMR Surgical (CMR) announced the completion of a $600 million Series D financing
.

The round was co-led by SoftBank Vision Fund 2 and Ally Bridge Group, with participation from investors including RPMI Railpen, Tencent and Chimera

Surgical Robotic Minimally Invasive Surgery .

Funding amount: $540 million

Round: F round

In May 2021, Noom announced a $540 million Series F financing
.

The round was led by Silver Lake with participation from Oak HC/FT, Temasek, Sequoia Capital, Novo Holdings, RRE and Samsung Ventures

Stress, anxiety, diabetes, high blood pressure and poor sleep

4.
XtalPi

Funding amount: $400 million

Financing round: D round

Jingtai Technology completed a USD 400 million Series D financing in August 2021, which was jointly led by OrbiMed Healthcare Fund Management Company and HOPU Investments
.

In the past year, Jingtai Technology has reached cooperation with companies such as Sedec Therapeutic and Acerand Therapeutics to promote innovative drug discovery in the field of cancer and autoimmune diseases

5.
insitro

Funding amount: $400 million

Financing round: C round

In March 2021, insitro announced the completion of a $400 million Series C financing
.

Founded by Dr.

Using Machine Learning to Drive Drug Discovery and Development of Stem Cell Models for Amyotrophic Lateral Sclerosis, Dementia and Nonalcoholic Steatohepatitis Neurodegenerative Diseases

6.
Kry Corporation

Financing Finance: $316 million

Financing round: D round

Kry completed a $316 million Series D financing in April 2021, with investors including CPP Investments, Fidelity Management & Research,
etc.
Kry's platform connects patients and their healthcare providers remotely through video consultations and instant messaging
.
New features introduced on the platform from last year include new patient matching and triage tools for physicians, expanded support for patient mental health and chronic health conditions, a feature that helps give patients wider access to psychologists, Dermatologists, physical therapists, paediatricians, etc.
, to provide patients with a more personalized treatment plan
.

Connect patients and their healthcare providers remotely through video consultations and instant messaging

7.
Freenome Corporation

Funding amount: $300 million

Financing round: D round

In December 2021, Freenome announced that it had received $300 million in Series D funding
.
Freenome is an early stage cancer blood screening company focused on developing simple and accurate multi-omics blood tests
.
The company's multi-omics platform targets key biological signals in blood, analyzing cell-free DNA (cfDNA), DNA methylation levels, and protein biomarkers
.
The company's first test to date has been shown to detect stage 1 and 2 colorectal adenocarcinoma (94% sensitivity) and advanced colorectal cancer (91% sensitivity)
.
The new round of financing will support the advancement of the company's colorectal cancer screening test and the expansion of its multi-omics platform to other cancers
.

Early Cancer Blood Screening Colorectal Cancer Screening Test

8.
Element Biosciences

Funding amount: $276 million

Financing round: C round

In June 2021, Element Biosciences announced the completion of a $276 million Series C financing
.
Element, an emerging DNA sequencer developer , is developing a modular and high-performance DNA sequencing platform that can provide high-quality data, flexible workflows, and make next-generation sequencing technologies more accessible
.
The latest funding will help Element prepare for its imminent commercialization of its first desktop analytics platform
.

DNA sequencer developer to commercialize first benchtop analysis platform

9.
Oxford Nanopore Technologies

Funding Amount: $271 million

Funding round: Undisclosed

In May 2021, Oxford Nanopore Technologies completed a new round of financing of US$271 million, with investors including IP Group, Temasek, Wellington Management, M&G Investments, Nikon,
etc.
Oxford Nanopore is a developer and manufacturer of DNA/RNA sequencers .
Its nanopore sequencing platform can analyze a single RNA or DNA molecule at a time and can be used to classify brain tumors, sequence chromosomes, track the spread of infectious diseases, and more
.
In a study published by the company in March 2022, for example, researchers were able to use gene sequencing technology to create a test that could screen for more than 50 inherited neurological and neuromuscular diseases at once—cutting the traditional diagnosis time weeks or even years
.

Developer and manufacturer of DNA/RNA sequencers Nanopore sequencing platform can screen more than 50 genetic neurological and neuromuscular diseases at a time

10.
Imperative Care

Funding amount: $260 million

Financing round: D round

In July 2021, Imperative Care announced the completion of a $260 million Series D financing led by D1 Capital Partners LP
.
The company addresses the huge and urgent unmet need in stroke care by developing a range of innovative solutions
.
Its line of access catheters are FDA-cleared 510(k) and are designed to facilitate access to blood vessels in the brain; the ZOOM aspiration system is also FDA-cleared and is designed to facilitate thrombus removal during ischemic stroke
.
Proceeds from the new funding round will be used to support the continued development and commercialization of Imperative Care's broad range of stroke care technologies
.

Stroke Care

Original link: https://

https://

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.